Result of General Meeting

RNS Number : 2524B

Advanced Oncotherapy PLC

31 March 2017

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Result of General Meeting

Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that at the General Meeting held earlier today all resolutions were passed.

As a result the Board now has authority to utilise the Equity Financing Facility provided by Bracknor, details of which were provided in the 22 February 2017 announcement.

The Company continues to consider a number of financing options in addition to the Bracknor facility and the financing agreement with Blackfinch Investment Limited that was announced on 27 March 2017.

For further information, please contact:

Advanced Oncotherapy plc	www.avoplc.com
Nicolas Serandour, Chief Executive Officer	Tel: [phone]
Michael Sinclair, Executive Chairman
Stockdale Securities (Nomad & Joint Broker)	Tel: [phone]
Antonio Bossi / David Coaten
Stifel Nicolaus Europe (Joint Broker)	Tel: [phone]
Jonathan Senior / Ben Maddison
Walbrook PR (Financial PR & IR)	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Anna Dunphy	Mob: [phone]

About Advanced Oncotherapy plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac for Image Guided Hadron Therapy (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

ROMQFLFXDXFBBBK